Thrombosis

Individuals with at least one laboratory-confirmed respiratory infection had a higher risk of MI or stroke, in particular when infected with S. pneumoniae or influenza virus.

Different measures of fitness and physical activity were inversely associated with future CVD events and all-cause death, also in individuals with a high genetic CVD predisposition.

In the AXAFA-AFNET 5 trial, continuous apixaban therapy was non-inferior to continuous VKA treatment in terms of stroke, bleedings, cognitive function and MRI-detected acute brain lesions.

Introduction and m...

In a large prospective study, risk of all-cause mortality increases above 100 g alcohol per week, and positive associations with alcohol intake were seen mostly for stroke and HF, as opposed to MI.

Visit-to-visit variability in fasting measurements of HDL-c, TG, and LDL-c is predictive of coronary events, CV events, and TG and LDL-c variability is also predictive of incident diabetes.

Introduction and methods

Lon...

Neither FH mutations, nor high LDL-c levels were associated with an increased risk of ischemic stroke, with the exception of patients with a history of ischemic heart disease.

Mendelian randomization study suggests that lowering LDL affects large artery atherosclerosis, but not small artery occlusion or cardioembolic stroke, while increasing HDL may benefit small artery disease.

Introduction a...

Incident atrial fibrillation (AF) is associated with both greater cognitive decline and increased risk of dementia compared with individuals without AF, independent of clinical ischemic stroke.

Four Heart Rhythm Societies have composed a consensus statement on how to prevent, assess and treat cognitive decline in atrial fibrillation and other arrhythmias.

The European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS) have publis...

Following the results from the FOURIER trial, EMA’s CHMP has issued a positive opinion for the PCSK9 inhibitor evolocumab to reduce CV risk in patients with established ASCVD.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the PCSK9 inhibitor evolocumab to reduce CV risk...

The European Heart Rhythm Association (EHRA) updated its practical guide on use of non-vitamin K antagonist oral anticoagulants in specific clinical situations and particular patient groups.

A new version of the EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation was published in European Heart Jo...

New data of the ongoing GLORIA-AF registry on use of dabigatran in AF show low rates of major bleeding and stroke, and long-term safety data are consistent with other real-world and RCT evidence.

New data from the prospective ongoing Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Registry showed low rates of major...

ACC 2018 In an interim analysis of the ANNEXA-4 study, andexanet rapidly reversed anti-FXa activity with an acceptable rate of adverse events in patients on FXa inhibitors with major bleeding.

Introduction and methods

Factor Xa (FXa) inhibitors are...

ACC 2018 In the digital mSToPS trial using patient-generated data, a wearable ECG patch improved the rate of AF diagnosis at 1 year compared to routine care.

ACC 2018 When clinical characteristics were combined with genetic information to inform the choice of P2Y12 inhibitor after ACS, patients experienced 42% fewer MI, stroke, CV death or major bleeding.

Background

The eff...

ACC 2018 Treatment with canakinumab reduced MACE+ in patients with CKD in the CANTOS trial, with a stronger reduction in those who achieved on-treatment hsCRP<2 mg/mL compared to >2 mg/mL.

Introduction and methods

Patients with chronic kidney disea...